Full Press Release Details
Inventiva secures a 50
million credit facility from the
European Investment Bank
Daix (France), Long Island City (New York,
United States), May 16, 2022 - Inventiva (Euronext Paris and Nasdaq: IVA) (the "Company"), a clinical-stage
biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with non-alcoholic
steatohepatitis (NASH) and other diseases with significant unmet medical needs, today announced the signing of a 50 million bullet
credit facility agreement with the European Investment Bank ("EIB"). The Company plans to use the facility toward its preclinical
and clinical pipeline, including to help fund a portion of its Phase III clinical trial of lanifibranor in patients with NASH.
The facility is divided into two tranches of
25 million each. The disbursement of the first tranche ("Tranche A") is subject to the completion of certain conditions
precedent specified in the credit facility agreement. The second tranche ("Tranche B") is subject to the full drawdown of
Tranche A in addition to the achievement of certain conditions precedents. The maturity date of any borrowings under the facility is
four years after disbursement of Tranche A and three years after disbursement of Tranche B. It is therefore expected that the reimbursement
of the interests and capital of this credit facility will happen after the publication of the headline results of the part 1 of the Phase
III clinical trial of lanifibranor in patients with NASH, which are expected in the second half of 2024.
Jean Volatier, Chief Financial Officer of
Inventiva, stated: "We are very pleased with this credit facility, one of the largest granted by the EIB to a biotech. We
expect to use any borrowings under the facility to support further development of our pipeline, especially the clinical development of
lanifibranor to seek accelerated approval in the US and conditional approval in the EU."
"EIB is proud to finance a European
biotech company that is at the forefront of innovation in its field and embodies Europe's dynamism in the development of new treatments,
said Ambroise Fayolle, Vice-President of the European Investment Bank. The expertise developed by Inventiva is all the more
necessary as it aims to develop breakthrough treatments for patients suffering from NASH and other diseases with unmet medical needs
In addition to capitalized interest of 8% for
Tranche A and 7% for Tranche B, Inventiva will issue warrants to the benefit of the EIB in varied amounts according to the relevant tranche,
the amount of equity raised or the amount of cash received in the context of a partnership or other transaction and the average price
per share paid by investors in the context of the equity raise1
The strike price of each warrant will be equal
to 95% of the volume weighted average of the trading price of Inventiva's ordinary shares over a number of trading days preceding
the day the issue price is set. The warrants will have a term of 12 years and become exercisable upon the maturity of Tranche A or upon
Or in the absence of share issuance for the first tranche, the average price per share over the last 90 trading days preceding
the subscription of the warrants.
certain events (e.g., change of control, event
of default repayment demand), thus avoiding dilution for existing shareholders in the near term.
At the maturity of Tranche A or upon the occurrence
of certain events, the EIB will be granted an option to sell its warrants to Inventiva for an amount equal to the difference between
the fair market value and the exercise price of the warrants2,
as an alternative to the exercise of the warrants.
About the European Investment
The EIB is the European Union (EU) long-term
financing institution, and its shareholders are the 27 EU Member States. Its mission is to contribute to the integration, balanced development,
and economic and social cohesion of EU Member States. It borrows large volumes of funds from the capital markets and lends them with
very favourable terms to support projects which contribute to the achievement of EU objectives. The EIB is working to put the EU at the
forefront of the next wave of innovation, especially in the health sector. In response to the Covid-19 health crisis, the EIB has released
6 billion for investments in the health sector to support medical infrastructure, additional research activities or other financing
related to vaccines and treatments. As a European bank supporting the climate, the EIB is one of the main fund providers in the green
transition towards a more low-carbon and sustainable growth model.
Inventiva is a clinical-stage biopharmaceutical
company focused on the research and development of oral small molecule therapies for the treatment of patients with NASH and other diseases
with significant unmet medical needs. The Company benefits from a strong expertise and experience in the domain of compounds targeting
nuclear receptors, transcription factors and epigenetic modulation. Inventiva's lead product candidate, lanifibranor, is currently
in a pivotal Phase III clinical trial, NATiV3, for the treatment of adult patients with NASH, a common and progressive chronic liver
disease for which there are currently no approved therapies.
Company has established a strategic collaboration with AbbVie in the area of autoimmune diseases that resulted in the discovery of the
drug candidate cedirogant (ABBV-157), an oral RORg inverse
agonist which is being evaluated in a Phase IIb clinical trial, led by AbbVie, in adult patients with moderate to severe chronic plaque
psoriasis. Inventiva's pipeline also includes odiparcil, a drug candidate for the treatment of adult mucopolysaccharidoses (MPS)
VI patients. As part of Inventiva's decision to focus clinical efforts on the development of lanifibranor, it suspended its clinical
efforts relating to odiparcil and is reviewing available options with respect to its potential further development. Inventiva is in the
process of selecting an oncology development candidate for its Hippo signalling pathway program.
The Company has a scientific team of approximately
80 people with deep expertise in the fields of biology, medicinal and computational chemistry, pharmacokinetics and pharmacology, and
clinical development. It owns an extensive library of approximately 240,000 pharmacologically relevant molecules, approximately 60% of
which are proprietary, as well as a wholly owned research and development facility.
Inventiva is a public company listed on compartment
C of the regulated market of Euronext Paris (ticker: IVA - ISIN: FR0013233012) and on the Nasdaq Global Market in the United States (ticker:
IVA). www.inventivapharma.com.
to a cap equal to the aggregate amount disbursed under the credit facility agreement.
This press release contains "forward-looking
statements" within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements,
other than statements of historical facts, included in this press release are forward-looking statements. These statements include, but
are not limited to, forecasts and estimates with respect to Inventiva's pre-clinical programs and clinical trials, clinical trial
data releases, including for part 1 of the Phase III clinical trial of lanifibranor in patients with NASH, pipeline and preclinical and
clinical development plans, reaching anticipated milestones and conditions precedent for Tranche A and/or Tranche B, potential future
financings and strategic transactions, milestone payments, royalties and product sales, future activities, expectations, plans, growth
and prospects of Inventiva and the sufficiency of Inventiva's cash resources and cash runway. Certain of these statements, forecasts
and estimates can be recognized by the use of words such as, without limitation, "believes", "anticipates", "expects",
"intends", "plans", "seeks", "estimates", "may", "will", "would",
"could", "might", "should", and "continue" and similar expressions. Such statements are
not historical facts but rather are statements of future expectations and other forward-looking statements that are based on management's
beliefs. These statements reflect such views and assumptions prevailing as of the date of the statements and involve known and unknown
risks and uncertainties that could cause future results, performance or future events to differ materially from those expressed or implied
in such statements. Future events are difficult to predict and may depend upon factors that are beyond Inventiva's control. There can
be no guarantees with respect to pipeline product candidates that the clinical trial results will be available on their anticipated timeline,
that future clinical trials will be initiated as anticipated, that product candidates will receive the necessary regulatory approvals,
or that any of the anticipated milestones by Inventiva or its partners will be reached or that conditions precedent to receive funds
under the credit facility will be met on their expected timeline, or at all. Actual results may turn out to be materially different from
the anticipated future results, performance or achievements expressed or implied by such statements, forecasts and estimates, due to
a number of factors, including that Inventiva is a clinical-stage company with no approved products and no historical product revenues,
Inventiva has incurred significant losses since inception, Inventiva has a limited operating history and has never generated any revenue
from product sales, Inventiva will require additional capital to finance its operations, Inventiva's future success is dependent on the
successful clinical development, regulatory approval and subsequent commercialization of current and any future product candidates, preclinical
studies or earlier clinical trials are not necessarily predictive of future results and the results of Inventiva's clinical trials may
not support Inventiva's product candidate claims, Inventiva may encounter substantial delays in its clinical trials or Inventiva may
fail to demonstrate safety and efficacy to the satisfaction of applicable regulatory authorities, enrolment and retention of patients
in clinical trials is an expensive and time-consuming process and could be made more difficult or rendered impossible by multiple factors
outside Inventiva's control, Inventiva's product candidates may cause adverse drug reactions or have other properties that could delay
or prevent their regulatory approval, or limit their commercial potential, Inventiva faces substantial competition and Inventiva's
business, and preclinical studies and clinical development programs and timelines, its financial condition and results of operations